182 related articles for article (PubMed ID: 37568727)
1. Recent Progress in Modulation of WD40-Repeat Domain 5 Protein (WDR5): Inhibitors and Degraders.
Gurung R; Om D; Pun R; Hyun S; Shin D
Cancers (Basel); 2023 Aug; 15(15):. PubMed ID: 37568727
[TBL] [Abstract][Full Text] [Related]
2. Discovery of Potent Small-Molecule Inhibitors of WDR5-MYC Interaction.
Ding J; Li G; Liu H; Liu L; Lin Y; Gao J; Zhou G; Shen L; Zhao M; Yu Y; Guo W; Hommel U; Ottl J; Blank J; Aubin N; Wei Y; He H; Sage DR; Atadja PW; Li E; Jain RK; Tallarico JA; Canham SM; Chiang YL; Wang H
ACS Chem Biol; 2023 Jan; 18(1):34-40. PubMed ID: 36594833
[TBL] [Abstract][Full Text] [Related]
3. Targeted Disruption of the Interaction between WD-40 Repeat Protein 5 (WDR5) and Mixed Lineage Leukemia (MLL)/SET1 Family Proteins Specifically Inhibits MLL1 and SETd1A Methyltransferase Complexes.
Alicea-Velázquez NL; Shinsky SA; Loh DM; Lee JH; Skalnik DG; Cosgrove MS
J Biol Chem; 2016 Oct; 291(43):22357-22372. PubMed ID: 27563068
[TBL] [Abstract][Full Text] [Related]
4. Discovery and Structure-Based Design of Inhibitors of the WD Repeat-Containing Protein 5 (WDR5)-MYC Interaction.
Ding J; Liu L; Chiang YL; Zhao M; Liu H; Yang F; Shen L; Lin Y; Deng H; Gao J; Sage DR; West L; Llamas LA; Hao X; Kawatkar S; Li E; Jain RK; Tallarico JA; Canham SM; Wang H
J Med Chem; 2023 Jun; 66(12):8310-8323. PubMed ID: 37307526
[TBL] [Abstract][Full Text] [Related]
5. Structure-based discovery of potent WD repeat domain 5 inhibitors that demonstrate efficacy and safety in preclinical animal models.
Teuscher KB; Chowdhury S; Meyers KM; Tian J; Sai J; Van Meveren M; South TM; Sensintaffar JL; Rietz TA; Goswami S; Wang J; Grieb BC; Lorey SL; Howard GC; Liu Q; Moore WJ; Stott GM; Tansey WP; Lee T; Fesik SW
Proc Natl Acad Sci U S A; 2023 Jan; 120(1):e2211297120. PubMed ID: 36574664
[TBL] [Abstract][Full Text] [Related]
6. Discovery and Structure-Based Optimization of Potent and Selective WD Repeat Domain 5 (WDR5) Inhibitors Containing a Dihydroisoquinolinone Bicyclic Core.
Tian J; Teuscher KB; Aho ER; Alvarado JR; Mills JJ; Meyers KM; Gogliotti RD; Han C; Macdonald JD; Sai J; Shaw JG; Sensintaffar JL; Zhao B; Rietz TA; Thomas LR; Payne WG; Moore WJ; Stott GM; Kondo J; Inoue M; Coffey RJ; Tansey WP; Stauffer SR; Lee T; Fesik SW
J Med Chem; 2020 Jan; 63(2):656-675. PubMed ID: 31858797
[TBL] [Abstract][Full Text] [Related]
7. Interaction with WDR5 promotes target gene recognition and tumorigenesis by MYC.
Thomas LR; Wang Q; Grieb BC; Phan J; Foshage AM; Sun Q; Olejniczak ET; Clark T; Dey S; Lorey S; Alicie B; Howard GC; Cawthon B; Ess KC; Eischen CM; Zhao Z; Fesik SW; Tansey WP
Mol Cell; 2015 May; 58(3):440-52. PubMed ID: 25818646
[TBL] [Abstract][Full Text] [Related]
8. A selective WDR5 degrader inhibits acute myeloid leukemia in patient-derived mouse models.
Yu X; Li D; Kottur J; Shen Y; Kim HS; Park KS; Tsai YH; Gong W; Wang J; Suzuki K; Parker J; Herring L; Kaniskan HÜ; Cai L; Jain R; Liu J; Aggarwal AK; Wang GG; Jin J
Sci Transl Med; 2021 Sep; 13(613):eabj1578. PubMed ID: 34586829
[TBL] [Abstract][Full Text] [Related]
9. Structural basis for WDR5 interaction (Win) motif recognition in human SET1 family histone methyltransferases.
Dharmarajan V; Lee JH; Patel A; Skalnik DG; Cosgrove MS
J Biol Chem; 2012 Aug; 287(33):27275-89. PubMed ID: 22665483
[TBL] [Abstract][Full Text] [Related]
10. Loss of Wdr5 attenuates MLL-rearranged leukemogenesis by suppressing Myc targets.
Liu L; Guo X; Wang Y; Li G; Yu Y; Song Y; Zeng C; Ding Z; Qiu Y; Yan F; Zhang YX; Zhao C; Zhang Y; Dou Y; Atadja P; Li E; Wang H
Biochim Biophys Acta Mol Basis Dis; 2023 Feb; 1869(2):166600. PubMed ID: 36402263
[TBL] [Abstract][Full Text] [Related]
11. Overlapping characteristics of weak interactions of two transcriptional regulators with WDR5.
Ahmad M; Imran A; Movileanu L
Int J Biol Macromol; 2024 Feb; 258(Pt 2):128969. PubMed ID: 38158065
[TBL] [Abstract][Full Text] [Related]
12. Interaction of the oncoprotein transcription factor MYC with its chromatin cofactor WDR5 is essential for tumor maintenance.
Thomas LR; Adams CM; Wang J; Weissmiller AM; Creighton J; Lorey SL; Liu Q; Fesik SW; Eischen CM; Tansey WP
Proc Natl Acad Sci U S A; 2019 Dec; 116(50):25260-25268. PubMed ID: 31767764
[TBL] [Abstract][Full Text] [Related]
13. Discovery, evaluation and mechanism study of WDR5-targeted small molecular inhibitors for neuroblastoma.
Han QL; Zhang XL; Ren PX; Mei LH; Lin WH; Wang L; Cao Y; Li K; Bai F
Acta Pharmacol Sin; 2023 Apr; 44(4):877-887. PubMed ID: 36207403
[TBL] [Abstract][Full Text] [Related]
14. The Development of Inhibitors Targeting the Mixed Lineage Leukemia 1 (MLL1)-WD Repeat Domain 5 Protein (WDR5) Protein- Protein Interaction.
Ye X; Chen G; Jin J; Zhang B; Wang Y; Cai Z; Ye F
Curr Med Chem; 2020; 27(33):5530-5542. PubMed ID: 31132972
[TBL] [Abstract][Full Text] [Related]
15. Kinetics of the multitasking high-affinity Win binding site of WDR5 in restricted and unrestricted conditions.
Imran A; Moyer BS; Canning AJ; Kalina D; Duncan TM; Moody KJ; Wolfe AJ; Cosgrove MS; Movileanu L
Biochem J; 2021 Jun; 478(11):2145-2161. PubMed ID: 34032265
[TBL] [Abstract][Full Text] [Related]
16. The MYC-WDR5 Nexus and Cancer.
Thomas LR; Foshage AM; Weissmiller AM; Tansey WP
Cancer Res; 2015 Oct; 75(19):4012-5. PubMed ID: 26383167
[TBL] [Abstract][Full Text] [Related]
17. WDR5 facilitates EMT and metastasis of CCA by increasing HIF-1α accumulation in Myc-dependent and independent pathways.
Chen T; Li K; Liu Z; Liu J; Wang Y; Sun R; Li Z; Qiu B; Zhang X; Ren G; Xu Y; Zhang Z
Mol Ther; 2021 Jun; 29(6):2134-2150. PubMed ID: 33601056
[TBL] [Abstract][Full Text] [Related]
18. Synthesis, Optimization, and Evaluation of Novel Small Molecules as Antagonists of WDR5-MLL Interaction.
Bolshan Y; Getlik M; Kuznetsova E; Wasney GA; Hajian T; Poda G; Nguyen KT; Wu H; Dombrovski L; Dong A; Senisterra G; Schapira M; Arrowsmith CH; Brown PJ; Al-Awar R; Vedadi M; Smil D
ACS Med Chem Lett; 2013 Mar; 4(3):353-7. PubMed ID: 24900672
[TBL] [Abstract][Full Text] [Related]
19. Unique Role of the WD-40 Repeat Protein 5 (WDR5) Subunit within the Mixed Lineage Leukemia 3 (MLL3) Histone Methyltransferase Complex.
Shinsky SA; Cosgrove MS
J Biol Chem; 2015 Oct; 290(43):25819-33. PubMed ID: 26324722
[TBL] [Abstract][Full Text] [Related]
20. The plasticity of WDR5 peptide-binding cleft enables the binding of the SET1 family of histone methyltransferases.
Zhang P; Lee H; Brunzelle JS; Couture JF
Nucleic Acids Res; 2012 May; 40(9):4237-46. PubMed ID: 22266653
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
